HomeCompareCYCCP vs PM

CYCCP vs PM: Dividend Comparison 2026

CYCCP yields 5.94% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $28.9K in total portfolio value
10 years
CYCCP
CYCCP
● Live price
5.94%
Share price
$5.05
Annual div
$0.30
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.7K
Annual income
$0.61
Full CYCCP calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — CYCCP vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYCCPPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYCCP + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYCCP pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYCCP
Annual income on $10K today (after 15% tax)
$504.95/yr
After 10yr DRIP, annual income (after tax)
$0.52/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PM beats the other by $2,117.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYCCP + PM for your $10,000?

CYCCP: 50%PM: 50%
100% PM50/50100% CYCCP
Portfolio after 10yr
$35.1K
Annual income
$1,246.32/yr
Blended yield
3.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CYCCP
Analyst Ratings
4
Buy
1
Hold
Consensus: Buy
Altman Z
-74.5
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYCCP buys
0
PM buys
0
No recent congressional trades found for CYCCP or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYCCPPM
Forward yield5.94%3.48%
Annual dividend / share$0.30$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%17.2%
Portfolio after 10y$20.7K$49.6K
Annual income after 10y$0.61$2,492.02
Total dividends collected$604.00$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: CYCCP vs PM ($10,000, DRIP)

YearCYCCP PortfolioCYCCP Income/yrPM PortfolioPM Income/yrGap
1← crossover$10,997$297.03$11,648$408.29$651.00PM
2$11,919$152.64$13,589$495.90$1.7KPM
3$12,831$77.31$15,877$603.21$3.0KPM
4$13,768$38.89$18,580$734.88$4.8KPM
5$14,751$19.50$21,781$896.75$7.0KPM
6$15,794$9.76$25,578$1,096.12$9.8KPM
7$16,904$4.88$30,092$1,342.17$13.2KPM
8$18,090$2.44$35,470$1,646.46$17.4KPM
9$19,358$1.22$41,892$2,023.58$22.5KPM
10$20,713$0.61$49,578$2,492.02$28.9KPM

CYCCP vs PM: Complete Analysis 2026

CYCCPStock

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Full CYCCP Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CYCCP vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYCCP vs SCHDCYCCP vs JEPICYCCP vs OCYCCP vs KOCYCCP vs MAINCYCCP vs MOCYCCP vs BTICYCCP vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.